Abelacimab, formerly known as MAA868, represents a groundbreaking approach to managing thrombosis. This antithrombotic agent is a targeted monoclonal antibody that inhibits the integrin αIIbβ3, a critical player in https://www.targetmol.com/compound/abelacimab